Activation markers of connective tissue in Dupuytren's contracture: Relation to postoperative outcome

Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery

Volumn 37, Issue 5, 2003, Pages 283-292

  Wilbrand, Stephan ^a,c   Flodmark, Christina ^a   Ekbom, Anders ^b   Gerdin, Bengt ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Enkoping Hospital   (Sweden)

Author keywords

Collagen; Connective tissue; Dupuytren's contracture; Immunohistochemistry; Recurrence

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ALPHA5 INTEGRIN; COLLAGEN ANTIBODY; COLLAGEN TYPE 4; DESMIN; LAMININ ANTIBODY; PROCOLLAGEN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONNECTIVE TISSUE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MARKER; DUPUYTREN CONTRACTURE; FEMALE; HAND SURGERY; HEREDITY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTCOMES RESEARCH; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECURRENT DISEASE; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CONNECTIVE TISSUE; DUPUYTREN'S CONTRACTURE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN BIOSYNTHESIS; PROTEINS; RECURRENCE; TREATMENT OUTCOME;

EID: 0242330375     PISSN: 02844311     EISSN: None     Source Type: Journal    
DOI: 10.1080/02844310310000662     Document Type: Article

References (36)

1. Berndt A, Kosmehl H, Katenkamp D, Tauchmann V. Appearance of the myofibroblastic phenotype in Dupuytren's disease is associated with a fibronectin, laminin, collagen type IV and tenascin extracellular matrix. Pathobiology 1994; 62: 55-58.
2. Boyer MI, Gelberman RH. Complications of the operative treatment of Dupuytren's disease. Hand Clin 1999; 15: 161-166.
3. Brickley-Parsons D, Glimcher MJ, Smith RJ, Albin R, Adams JP. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. J Bone Joint Surg 1981; 63A: 787-797.
4. Chiu HF, McFarlane RM. Pathogenesis of Dupuytren's contracture: a correlative clinical-pathological study. J Hand Surg 1978; 3A: 1-10.
5. Darby I, Skalli O, Gabbiani G. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest 1990; 63: 21-29.
6. Flint MH, Gillard GC, Reilly HC. The glycosaminoglycans of Dupuytren's disease. Connect Tissue Res 1982; 9: 173-179.
7. Gehlsen KR, Dickerson K, Argraves WS, Engvall E, Ruoslahti E. Subunit structure of a laminin-binding integrin and localization of its binding site on laminin. J Biol Chem 1989; 264: 19034-19038.
8. Gordon S. Dupuytren's contracture: recurrence and extension following surgical treatment. Br J Plast Surg 1957; 51: 286-288.
9. Gudmundsson KG, Arngrimsson R, Sigfusson N, Bjornsson A, Jonsson T. Epidemiology of Dupuytren's disease: clinical, serological, and social assessment. The Reykjavik Study. J Clin Epidemiol 2000; 53: 291-296.
10. Hall PN, Fitzgerald A, Sterne GD, Logan AM. Skin replacement in Dupuytren's disease. J Hand Surg 1997; 22B: 193-197.
11. Hueston JT. Digital Wolfe grafts in recurrent Dupuytren's contracture. Plast Reconstr Surg 1962; 29: 342-344.
12. Hueston JT. Recurrent Dupuytren's contracture. Plast Reconstr Surg 1963; 31: 66-67.
13. Hueston JT, Seyfer A. Some medicolegal aspects of Dupuytren's contracture. Hand Clin 1991; 7: 617-632.
14. Ling R. The genetic factor in Dupuytren's disease. J Bone Joint Surg 1963; 45B: 709.
15. Luck JV. Dupuytren's contracture: a new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg 1959; 41A: 635-664.
16. Magro G, Fraggetta F, Colombatti A, Lanzafame S. Myofibroblasts and extracellular matrix glycoproteins in palmar fibromatosis. Gen Diagn Pathol 1997; 142: 185-190.
17. Magro G, Fraggetta F, Travali S, Lanzafame S. Immunohistochemical expression and distribution of alpha2beta1, alpha6beta1, alpha5beta1 integrins and their extracellular ligands, type IV collagen, laminin and fibronectin in palmar fibromatosis. Gen Diagn Pathol 1997; 143: 203-208.
18. McDonald JA, Broekelmann TJ, Matheke ML, Crouch E, Koo M, Kuhn C III. A monoclonal antibody to the carboxyterminal domain of procollagen type I visualizes collagen-synthesizing fibroblasts. Detection of an altered fibroblast phenotype in lungs of patients with pulmonary fibrosis. J Clin Invest 1986; 78: 1237-1244.
19. Meister P, Gokel JM, Remberger K. Palmar fibromatosis - "Dupuytren's contracture". A comparison of light electron and immunofluorescence microscopic findings. Pathol Res Pract 1979; 164: 402-412.
20. Melling M, Karimian-Teherani D, Mostler S, Behnam M, Sobal G, Menzel EJ. Changes of biochemical and biomechanical properties in Dupuytren disease. Arch Pathol Lab Med 2000; 124: 1275-1281.
21. Melling M, Reihsner R, Pfeiler W et al. Comparison of palmar aponeuroses from individuals with diabetes mellitus and Dupuytren's contracture. Anat Rec 1999; 255: 401-406.
22. Menzel EJ, Piza H, Zielinski C, Endler AT, Steffen C, Millesi H. Collagen types and anticollagen-antibodies in Dupuytren's disease. Hand 1979; 11: 243-248.
23. Millesi H. The clinical and morphological course of Dupuytren's disease. In: Hueston JT, Tubiana R, eds. Dupuytren's disease. Edinburgh: Churchill Livingstone, 1974: 46-60.
24. Nehls V, Drenckhahn D. The versatility of microvascular pericytes: from mesenchyme to smooth muscle? Histochemistry 1993; 99: 1-12.
25. Nézelof C. Histological aspects of Dupuytren's disease. In: Dupuytren's disease. New York: Churchill Livingstone, 1985: 82-85.
26. Norotte G, Apoil A, Travers V. A ten years follow-up of the results of surgery for Dupuytren's disease. A study of fifty-eight cases. Ann Chir Main 1988; 7: 277-281.
27. Notbohm H, Bigi A, Roveri N, Hoch J, Acil Y, Koch MH. Ultrastructural and biochemical modifications of collagen from tissue of Morbus Dupuytren patients. J Biochem 1995; 118: 405-410.
28. Osborn M, Weber K. Tumor diagnosis by intermediate filament typing: a novel tool for surgical pathology. Lab Invest 1983; 48: 372-394.
29. Prosser R, Conolly WB. Complications following surgical treatment for Dupuytren's contracture. J Hand Ther 1996; 9: 344-348.
30. Ross DC. Epidemiology of Dupuytren's disease. Hand Clin 1999; 15: 53-62.
31. Saar JD, Grothaus PC. Dupuytren's disease: an overview. Plast Reconstr Surg 2000; 106: 125-136.
32. Skoog T. Dupuytren's contraction. Thesis. Uppsala: Uppsala University, 1948.
33. Tomasek JJ, Vaughan MB, Haaksma CJ. Cellular structure and biology of Dupuytren's disease. Hand Clin 1999; 15: 21-34.
34. Tubiana R, Leclercq C. Recurrent Dupuytren's disease. In: Dupuytren's disease. New York: Churchill Livingstone, 1985: 200-239.
35. Vande Berg JS, Gelberman RH, Rudolph R, Johnson D, Sicurello P. Dupuytren's disease: comparative growth dynamics and morphology between cultured myofibroblasts (nodule) and fibroblasts (cord). J Orthop Res 1984; 2: 247-256.
36. Viljanto J, Seppala PO, Lehtonen A. Chemical changes underlying Dupuytren's contracture. Ann Rheum Dis 1971; 30: 423-427.